Results for the intent-to-treat population; includes 619 patients (25.2%) who crossed over to letrozole from tamoxifen. § Results for the censored population (with 95% CI); excludes crossover ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Weekly administration of prophylactic tamoxifen is much less effective than the standard daily regimen in preventing the adverse breast effects induced by bicalutamide. Bicalutamide monotherapy is ...

following tamoxifen for 2–3 years (early 'switch' treatment) or 5 years (extended adjuvant treatment). Reducing recurrence risk is a primary goal of adjuvant hormonal therapy. There is an early ...